Allied Minds portfolio company OcuTerra Therapeutics has secured $14.6m in funding.

OcuTerra Therapeutics, a US-based ophthalmology drug developer based on research at Harvard University, has completed a $14.6m series B round. Investors in the round have not been identified. Founded in 2011 as SciFluor Life Sciences, OcuTerra is working on a treatment, OTT166, for diabetic retinopathy, a condition affecting the back of the eye. It is…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.